Michael Zdanowski's most recent trade in Talaris Therapeutics Inc was a trade of 150,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 1, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Talaris Therapeutics Inc | Michael Zdanowski | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Talaris Therapeutics Inc | Michael Zdanowski | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 150,000 | 150,000 | - | - | Stock Appreciation Right | |
| Talaris Therapeutics Inc | Michael Zdanowski | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2022 | 120,000 | 121,470 | - | 0 | Common Stock | |
| Talaris Therapeutics Inc | Michael Zdanowski | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Talaris Therapeutics Inc | Michael Zdanowski | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 13.00 per share. | 01 Feb 2022 | 1,470 | 1,470 | - | 13 | 19,110 | Common Stock |